A commentary on “Antipsychotic-induced Parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders”

In a recent study, Potvin et al. (2014) used a multivariate statistical approach to identify socio-demographic, neurological, drug induced extrapyramidal symptoms (EPS), and psychiatric predictors of cognitive impairments in patients with a DSM-IV diagnosis of schizophrenia (aged 18–60). Specifically, the study focused on antipsychotic-induced EPS, such as Parkinsonism which is characterized by hypokinesia, tremors, muscle rigidity, and/or bradykinesia (Tandon and Jibson, 2002). EPS were assessed with the Extrapyramidal Symptoms Rating Scale (ESRS; Chouinard and Margolese, 2005) and neurocognition was measured using the Cambridge Neuropsychological Test Automated Battery (CANTAB, Eclipse version 2.0; Elliott et al., 1998). The depressive and psychiatric symptoms of schizophrenia were evaluated using the Calgary Depression Scale for Schizophrenia (CDSS; Addington et al., 1992) and the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987)